XML 71 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1
Business Combinations - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Oct. 01, 2024
Dec. 12, 2023
Oct. 10, 2023
Jun. 20, 2023
Dec. 28, 2022
Jan. 03, 2022
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Business Combinations                      
Goodwill             $ 716,333,000 $ 716,333,000 $ 757,038,000 $ 716,333,000 $ 717,743,000
Contingent consideration             54,457,000 54,457,000 43,939,000 54,457,000  
Payment for contingent consideration liability                 15,156,000 0 0
Change in fair value of contingent considerations                 8,089,000 24,118,000 0
Revenues                 385,148,000 354,337,000 335,644,000
Net income (loss) available to common shareholders                 (12,051,000) (55,357,000) $ 14,731,000
Integrated Nonclinical Development Solutions, Inc.                      
Business Combinations                      
Business consideration transferred           $ 8,048,000          
Goodwill           2,910,000          
Vyasa Analytics, LLC                      
Business Combinations                      
Business consideration transferred         $ 29,276,000            
Goodwill         $ 16,589,000            
Contingent consideration earn-out period         3 years            
Contingent consideration percentage of consideration paid in cash (as a percent)         70.00%            
Contingent consideration percentage of consideration paid in stock (as a percent)         30.00%            
Contingent consideration             45,249,000 45,249,000 43,939,000 45,249,000  
Payment for contingent consideration liability                 12,356,000    
Payment for contingent consideration liability, portion paid in cash                 8,649,000    
Payment for contingent consideration liability, portion paid in stock                 3,707,000    
Vyasa Analytics, LLC | Revenue Target                      
Business Combinations                      
Contingent consideration         $ 19,813,000            
Vyasa Analytics, LLC | Minimum                      
Business Combinations                      
Contingent consideration payout based on revenue threshold achievement                 0    
Vyasa Analytics, LLC | Maximum                      
Business Combinations                      
Contingent consideration payout based on revenue threshold achievement                 60,000,000    
Drug Interaction Solutions University of Washington (DIDB)                      
Business Combinations                      
Business consideration transferred       $ 8,340,000              
Goodwill       $ 2,289,000              
Contingent consideration earn-out period       2 years              
Contingent consideration                 132,000    
Change in fair value of contingent considerations               (658,000) (132,000)    
Contingent consideration arrangements, range of outcomes, value, high       $ 2,000,000              
Drug Interaction Solutions University of Washington (DIDB) | Revenue Target                      
Business Combinations                      
Contingent consideration       790,000              
Formedix                      
Business Combinations                      
Business consideration transferred     $ 41,389,000                
Goodwill     $ 25,062,000                
Contingent consideration earn-out period     2 years                
Contingent consideration     $ 5,161,000       3,696,000 3,696,000 0 3,696,000  
Change in fair value of contingent considerations             (684,000)   (1,919,000)    
Tax contingencies                 529,000    
Contingent consideration arrangements, range of outcomes, value, high     9,000,000                
Formedix | Revenue Target                      
Business Combinations                      
Contingent consideration     4,380,000                
Applied Biomath                      
Business Combinations                      
Business consideration transferred   $ 36,594,000                  
Goodwill   $ 15,872,000                  
Contingent consideration earn-out period   2 years                  
Contingent consideration             $ 5,380,000 $ 5,380,000 0 5,380,000  
Change in fair value of contingent considerations                 (650,000) 23,000  
Contingent consideration arrangements, range of outcomes, value, high   $ 17,550,000                  
Applied Biomath | Revenue Target                      
Business Combinations                      
Contingent consideration   5,357,000                  
Payment for contingent consideration liability                 4,730,000    
Chemaxon, Kft.                      
Business Combinations                      
Business consideration transferred $ 96,401,000                    
Goodwill $ 46,483,000                    
Equity acquired (as percentage) 100.00%                    
Purchase consideration adjustment                 531,000    
Transaction costs                 1,652,000    
Revenues                 6,561,000    
Net income (loss) available to common shareholders                 1,127,000    
Chemaxon, Kft. | Acquisition-related Costs                      
Business Combinations                      
Revenues                 (244,000) 1,494,000  
Amortization                 2,317,000 3,712,000  
General and administrative expenses | Vyasa Analytics, LLC                      
Business Combinations                      
Change in fair value of contingent considerations                 11,046,000 $ 25,436,000  
Customer relationships | Integrated Nonclinical Development Solutions, Inc.                      
Business Combinations                      
Finite-lived intangible assets acquired           2,380,000          
Customer relationships | Vyasa Analytics, LLC                      
Business Combinations                      
Finite-lived intangible assets acquired         1,500,000            
Customer relationships | Drug Interaction Solutions University of Washington (DIDB)                      
Business Combinations                      
Finite-lived intangible assets acquired       360,000              
Customer relationships | Formedix                      
Business Combinations                      
Finite-lived intangible assets acquired     3,100,000                
Customer relationships | Applied Biomath                      
Business Combinations                      
Finite-lived intangible assets acquired   13,700,000                  
Non-compete agreements | Integrated Nonclinical Development Solutions, Inc.                      
Business Combinations                      
Finite-lived intangible assets acquired           100,000          
Non-compete agreements | Vyasa Analytics, LLC                      
Business Combinations                      
Finite-lived intangible assets acquired         80,000            
Non-compete agreements | Applied Biomath                      
Business Combinations                      
Finite-lived intangible assets acquired   800,000                  
Developed technology | Integrated Nonclinical Development Solutions, Inc.                      
Business Combinations                      
Finite-lived intangible assets acquired           $ 1,040,000          
Developed technology | Vyasa Analytics, LLC                      
Business Combinations                      
Finite-lived intangible assets acquired         11,400,000            
Developed technology | Drug Interaction Solutions University of Washington (DIDB)                      
Business Combinations                      
Finite-lived intangible assets acquired       5,600,000              
Developed technology | Formedix                      
Business Combinations                      
Finite-lived intangible assets acquired     $ 11,700,000                
Payment for contingent consideration liability                 $ 1,777,000    
Developed technology | Applied Biomath                      
Business Combinations                      
Finite-lived intangible assets acquired   $ 4,600,000                  
Trademarks | Vyasa Analytics, LLC                      
Business Combinations                      
Finite-lived intangible assets acquired         $ 120,000            
Trademarks | Drug Interaction Solutions University of Washington (DIDB)                      
Business Combinations                      
Finite-lived intangible assets acquired       $ 330,000